Literature DB >> 23046151

Soluble mediators released by acute myeloid leukemia cells increase capillary-like networks.

Kimberley J Hatfield1, Lasse Evensen, Håkon Reikvam, James B Lorens, Øystein Bruserud.   

Abstract

Increased bone marrow angiogenesis is seen in several hematological malignancies, including acute myeloid leukemia (AML). We used a co-culture assay of endothelial and vascular smooth muscle cells (vSMC) to investigate the effects of AML-conditioned medium on capillary networks. We investigated primary AML cells derived from 44 unselected patients and observed that for a large subset of patients, the constitutive cytokine release by the leukemic cells stimulated endothelial cell organization into capillary-like networks, while there were only minor or no effects for other patients. We analyzed the constitutive AML cell release of 31 cytokines for all the patients and performed a hierarchical cluster analysis of the cytokine profile which identified two major patient subsets that differed in their ability to enhance capillary-like networks; increased capillary-like networks was then associated with high constitutive release of several cytokines and especially high levels of several pro-angiogenic chemokines. Significantly increased network formation was not seen for any of the 11 acute lymphoblastic leukemia patients investigated. The cytokine response by activated normal T cells inhibited endothelial network formation in our in vitro model of angiogenesis and activated normal monocytes had only a minor influence on tube formation. Our study shows that AML-derived cytokines can induce the organization of endothelial cells into vessel-like structures.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23046151     DOI: 10.1111/ejh.12016

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  6 in total

Review 1.  Endothelial progenitor cells in hematologic malignancies.

Authors:  Ugo Testa; Ernestina Saulle; Germana Castelli; Elvira Pelosi
Journal:  Stem Cell Investig       Date:  2016-07-01

2.  Functional integration of acute myeloid leukemia into the vascular niche.

Authors:  Christopher R Cogle; Devorah C Goldman; Gerard J Madlambayan; Ronald P Leon; Azzah Al Masri; Hilary A Clark; Steven A Asbaghi; Jeffrey W Tyner; Jennifer Dunlap; Guang Fan; Tibor Kovacsovics; Qiuying Liu; Amy Meacham; Kimberly L Hamlin; Robert A Hromas; Edward W Scott; William H Fleming
Journal:  Leukemia       Date:  2014-03-18       Impact factor: 11.528

3.  A three-dimensional ex vivo tri-culture model mimics cell-cell interactions between acute myeloid leukemia and the vascular niche.

Authors:  Laura J Bray; Marcus Binner; Yvonne Körner; Malte von Bonin; Martin Bornhäuser; Carsten Werner
Journal:  Haematologica       Date:  2017-03-30       Impact factor: 9.941

4.  In leukemia, knock-down of the death inducer-obliterator gene would inhibit the proliferation of endothelial cells by inhibiting the expression of CDK6 and CCND1.

Authors:  Honghua Cao; Lilan Wang; Chengkui Geng; Man Yang; Wenwen Mao; Linlin Yang; Yin Ma; Ming He; Yeying Zhou; Lianqing Liu; Xuejiao Hu; Jingxing Yu; Xiufen Shen; Xuezhong Gu; Liefen Yin; Zhenglei Shen
Journal:  PeerJ       Date:  2022-02-01       Impact factor: 2.984

5.  Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells.

Authors:  Håkon Reikvam; Ina Nepstad; Øystein Bruserud; Kimberley Joanne Hatfield
Journal:  Oncotarget       Date:  2013-06

6.  In Vitro Characterization of Valproic Acid, ATRA, and Cytarabine Used for Disease-Stabilization in Human Acute Myeloid Leukemia: Antiproliferative Effects of Drugs on Endothelial and Osteoblastic Cells and Altered Release of Angioregulatory Mediators by Endothelial Cells.

Authors:  Hilde Kvestad; Lasse Evensen; James B Lorens; Oystein Bruserud; Kimberley J Hatfield
Journal:  Leuk Res Treatment       Date:  2014-01-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.